Announcements
- Medigene AG reports Financial Results and Business Update for Q1 2024
- Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
- Medigene to Present at Upcoming Scientific Conferences
- Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
- Medigene AG Secures European Patent for its iM-TCR Technology
- Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
- Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Medigene AG to report full year 2023 financial results on March 28, 2024
- Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
- Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
More ▼
Key statistics
On Tuesday, Medigene AG (MDG1:HAN) closed at 1.41, 6.44% above its 52-week low of 1.32, set on Jan 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.41 |
---|---|
High | 1.41 |
Low | 1.41 |
Bid | 1.39 |
Offer | 1.46 |
Previous close | 1.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 29.48m |
Free float | 28.61m |
P/E (TTM) | -- |
Market cap | 42.44m EUR |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 30 2024 07:16 BST.
More ▼